Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses

Journal of Immunology

Volumn 194, Issue 12, 2015, Pages 5895-5902

  Terhorst, Dorothea ^a,b,c,d   Fossum, Even ^e   Baranska, Anna ^a,b,c   Tamoutounour, Samira ^a,b,c   Malosse, Camille ^a,b,c   Garbani, Mattia ^f   Braun, Reinhard ^g   Lechat, Elmira ^g   Crameri, Reto ^f   Bogen, Bjarne ^e   Henri, Sandrine ^a,b,c   Malissen, Bernard ^a,b,c  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSERM   (France)

^c CNRS   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g Pantec Biosolutions AG   (Liechtenstein)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHEMOKINE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; VACCINE; XC CHEMOKINE RECEPTOR 1; XCL1 OVA VACCINE; CANCER VACCINE; CHEMOKINE RECEPTOR; GAMMA CHEMOKINE; OVALBUMIN; PROTEIN BINDING; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN; XC CHEMOKINE RECEPTOR 1, MOUSE; XCL1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; IMMUNIZATION; IMMUNOSTIMULATION; IN VIVO STUDY; LASER; MELANOMA; MOUSE; NONHUMAN; PORTABLE EQUIPMENT; PRECISE LASER EPIDERMAL SYSTEM; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; XCR1+ DENDRITIC CELL; ANIMAL; DISEASE MODEL; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR VOLUME;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; CANCER VACCINES; CHEMOKINES, C; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRADERMAL; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS; OVALBUMIN; PROTEIN BINDING; RECEPTORS, CHEMOKINE; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN;

EID: 84931319787     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500564     Document Type: Article

References (48)

1. Malissen, B., S. Tamoutounour, and S. Henri. 2014. The origins and functions of dendritic cells and macrophages in the skin. Nat. Rev. Immunol. 14: 417-428.
2. Haniffa, M., M. Collin, and F. Ginhoux. 2013. Ontogeny and functional specialization of dendritic cells in human and mouse. Adv. Immunol. 120: 1-49.
3. Satpathy, A. T., X. Wu, J. C. Albring, and K. M. Murphy. 2012. Re(de)fining the dendritic cell lineage. Nat. Immunol. 13: 1145-1154.
4. Merad, M., P. Sathe, J. Helft, J. Miller, and A. Mortha. 2013. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31: 563-604.
5. Dorner, B. G., M. B. Dorner, X. Zhou, C. Opitz, A. Mora, S. Güttler, A. Hutloff, H. W. Mages, K. Ranke, M. Schaefer, et al. 2009. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 31: 823-833.
6. Crozat, K., S. Tamoutounour, T. P. Vu Manh, E. Fossum, H. Luche, L. Ardouin, M. Guilliams, H. Azukizawa, B. Bogen, B. Malissen, et al. 2011. Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. J. Immunol. 187: 4411-4415.
7. Bachem, A., E. Hartung, S. Güttler, A. Mora, X. Zhou, A. Hegemann, M. Plantinga, E. Mazzini, P. Stoitzner, S. Gurka, et al. 2012. Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation. Front. Immunol. 3: 214.
8. Henri, S., L. F. Poulin, S. Tamoutounour, L. Ardouin, M. Guilliams, B. de Bovis, E. Devilard, C. Viret, H. Azukizawa, A. Kissenpfennig, and B. Malissen. 2010. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 207: 189-206.
9. Bedoui, S., P. G. Whitney, J. Waithman, L. Eidsmo, L. Wakim, I. Caminschi, R. S. Allan, M. Wojtasiak, K. Shortman, F. R. Carbone, et al. 2009. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 10: 488-495.
10. Zhang, J. G., P. E. Czabotar, A. N. Policheni, I. Caminschi, S. S. Wan, S. Kitsoulis, K. M. Tullett, A. Y. Robin, R. Brammananth, M. F. van Delft, et al. 2012. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity 36: 646-657.
11. Ahrens, S., S. Zelenay, D. Sancho, P. Hanč, S. Kjær, C. Feest, G. Fletcher, C. Durkin, A. Postigo, M. Skehel, et al. 2012. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 36: 635-645.
12. Dhodapkar, M. V., M. Sznol, B. Zhao, D. Wang, R. D. Carvajal, M. L. Keohan, E. Chuang, R. E. Sanborn, J. Lutzky, J. Powderly, et al. 2014. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci. Transl. Med. 6: 232ra51.
13. Caminschi, I., A. I. Proietto, F. Ahmet, S. Kitsoulis, J. Shin Teh, J. C. Lo, A. Rizzitelli, L. Wu, D. Vremec, S. L. van Dommelen, et al. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273.
14. Joffre, O. P., D. Sancho, S. Zelenay, A. M. Keller, and C. Reis e Sousa. 2010. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur. J. Immunol. 40: 1255-1265.
15. Hartung, E., M. Becker, A. Bachem, N. Reeg, A. Jäkel, A. Hutloff, H. Weber, C. Weise, C. Giesecke, V. Henn, et al. 2015. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J. Immunol. 194: 1069-1079.
16. Li, J., F. Ahmet, L. C. Sullivan, A. G. Brooks, S. J. Kent, R. De Rose, A. M. Salazar, C. Reis E Sousa, K. Shortman, M. H. Lahoud, et al. 2015. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur. J. Immunol. 45: 854-864.
17. Sancho, D., D. Mourão-Sá, O. P. Joffre, O. Schulz, N. C. Rogers, D. J. Pennington, J. R. Carlyle, and C. Reis e Sousa. 2008. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118: 2098-2110.
18. Sullivan, S. P., D. G. Koutsonanos, M. Del Pilar Martin, J. W. Lee, V. Zarnitsyn, S. O. Choi, N. Murthy, R. W. Compans, I. Skountzou, and M. R. Prausnitz. 2010. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16: 915-920.
19. Bachy, V., C. Hervouet, P. D. Becker, L. Chorro, L. M. Carlin, S. Herath, T. Papagatsias, J. B. Barbaroux, S. J. Oh, A. Benlahrech, et al. 2013. Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc. Natl. Acad. Sci. USA 110: 3041-3046.
20. Weiss, R., M. Hessenberger, S. Kitzmüller, D. Bach, E. E. Weinberger, W. D. Krautgartner, C. Hauser-Kronberger, B. Malissen, C. Boehler, Y. N. Kalia, et al. 2012. Transcutaneous vaccination via laser microporation. J. Control. Release 162: 391-399.
21. Fredriksen, A. B., and B. Bogen. 2007. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 110: 1797-1805.
22. Fossum, E., G. Grødeland, D. Terhorst, A. A. Tveita, E. Vikse, S. Mjaaland, S. Henri, B. Malissen, and B. Bogen. 2015. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus. Eur. J. Immunol. 45: 624-635.
23. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
24. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34-40.
25. Förster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Müller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99: 23-33.
26. Guilliams, M., K. Crozat, S. Henri, S. Tamoutounour, P. Grenot, E. Devilard, B. de Bovis, L. Alexopoulou, M. Dalod, and B. Malissen. 2010. Skin-draining lymph nodes contain dermis-derived CD103(-) dendritic cells that constitutively produce retinoic acid and induce Foxp3(+) regulatory T cells. Blood 115: 1958-1968.
27. Tamoutounour, S., M. Guilliams, F. Montanana Sanchis, H. Liu, D. Terhorst, C. Malosse, E. Pollet, L. Ardouin, H. Luche, C. Sanchez, et al. 2013. Origins and functional specialization of macrophages and of conventional and monocytederived dendritic cells in mouse skin. Immunity 39: 925-938.
28. Bach, D., R. Weiss, M. Hessenberger, S. Kitzmueller, E. E. Weinberger, W. D. Krautgartner, C. Hauser-Kronberger, C. Boehler, J. Thalhamer, and S. Scheiblhofer. 2012. Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice. Allergy 67: 1365-1374.
29. Brown, D. M., T. L. Fisher, C. Wei, J. G. Frelinger, and E. M. Lord. 2001. Tumours can act as adjuvants for humoral immunity. Immunology 102: 486-497.
30. Crozat, K., R. Guiton, V. Contreras, V. Feuillet, C. A. Dutertre, E. Ventre, T. P. Vu Manh, T. Baranek, A. K. Storset, J. Marvel, et al. 2010. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J. Exp. Med. 207: 1283-1292.
31. Shklovskaya, E., B. Roediger, and B. Fazekas de St Groth. 2008. Epidermal and dermal dendritic cells display differential activation and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo. J. Immunol. 181: 418-430.
32. Itano, A. A., S. J. McSorley, R. L. Reinhardt, B. D. Ehst, E. Ingulli, A. Y. Rudensky, and M. K. Jenkins. 2003. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19: 47-57.
33. Kissenpfennig, A., S. Henri, B. Dubois, C. Laplace-Builhé, P. Perrin, N. Romani, C. H. Tripp, P. Douillard, L. Leserman, D. Kaiserlian, et al. 2005. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22: 643-654.
34. Bachmann, M. F., and G. T. Jennings. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10: 787-796.
35. Gerner, M. Y., P. Torabi-Parizi, and R. N. Germain. 2015. Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. Immunity 42: 172-185.
36. Dalod, M., R. Chelbi, B. Malissen, and T. Lawrence. 2014. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming. EMBO J. 33: 1104-1116.
37. Kreutz, M., P. J. Tacken, and C. G. Figdor. 2013. Targeting dendritic cells - why bother? Blood 121: 2836-2844.
38. Kastenmüller, W., K. Kastenmüller, C. Kurts, and R. A. Seder. 2014. Dendritic cell-targeted vaccines - hope or hype? Nat. Rev. Immunol. 14: 705-711.
39. Flacher, V., C. H. Tripp, D. G. Mairhofer, R. M. Steinman, P. Stoitzner, J. Idoyaga, and N. Romani. 2014. Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance. EMBO Mol. Med. 6: 1191-1204.
40. Scheiblhofer, S., J. Thalhamer, and R. Weiss. 2013. Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. Expert Opin. Drug Deliv. 10: 761-773.
41. Woo, S. R., M. B. Fuertes, L. Corrales, S. Spranger, M. J. Furdyna, M. Y. Leung, R. Duggan, Y. Wang, G. N. Barber, K. A. Fitzgerald, et al. 2014. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41: 830-842.
42. Klarquist, J., C. M. Hennies, M. A. Lehn, R. A. Reboulet, S. Feau, and E. M. Janssen. 2014. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J. Immunol. 193: 6124-6134.
43. Broz, M. L., M. Binnewies, B. Boldajipour, A. E. Nelson, J. L. Pollack, D. J. Erle, A. Barczak, M. D. Rosenblum, A. Daud, D. L. Barber, et al. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26: 638-652.
44. Deng, L., H. Liang, M. Xu, X. Yang, B. Burnette, A. Arina, X. D. Li, H. Mauceri, M. Beckett, T. Darga, et al. 2014. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 41: 843-852.
45. Agace, W. W. 2006. Tissue-tropic effector T cells: generation and targeting opportunities. Nat. Rev. Immunol. 6: 682-692.
46. Bachem, A., S. Güttler, E. Hartung, F. Ebstein, M. Schaefer, A. Tannert, A. Salama, K. Movassaghi, C. Opitz, H. W. Mages, et al. 2010. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 207: 1273-1281.
47. Jongbloed, S. L., A. J. Kassianos, K. J. McDonald, G. J. Clark, X. Ju, C. E. Angel, C. J. Chen, P. R. Dunbar, R. B. Wadley, V. Jeet, et al. 2010. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207: 1247-1260.
48. Schlitzer, A., N. McGovern, P. Teo, T. Zelante, K. Atarashi, D. Low, A. W. Ho, P. See, A. Shin, P. S. Wasan, et al. 2013. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 38: 970-983.